While HF pharmacotherapy (SGLT2 inhibitors, RAAs inhibitors, MRAs) is proven to slow down the CKD and macroalbuminuria progression with proteinuria improvement, the concomitance of HF and CKD remains a serious clinical problem. Here, SLC5A2 is linked to chronic kidney disease.